☆ 4.6 Article

Prophylactic and Therapeutic Efficacy of Avian Antibodies Against Influenza Virus H5N1 and H1N1 in Mice

PLOS ONE (2010)

期刊

PLOS ONE

卷 5, 期 4, 页码 -

出版社

PUBLIC LIBRARY SCIENCE

DOI: 10.1371/journal.pone.0010152

关键词

类别

Multidisciplinary Sciences

资金

government of the Republic of Korea
government of Sweden
government of the Netherlands
government of Kuwait
Bill & Melinda Gates Foundation
Korean Healthcare Technology [A085105]
Ministry of Health and Welfare Family Affairs, Republic of Korea
Korea Research Council of Fundamental Science Technology [KGM3110912]
National Research Council of Science & Technology (NST), Republic of Korea [KGM3110912] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

摘要

Background: Pandemic influenza poses a serious threat to global health and the world economy. While vaccines are currently under development, passive immunization could offer an alternative strategy to prevent and treat influenza virus infection. Attempts to develop monoclonal antibodies (mAbs) have been made. However, passive immunization based on mAbs may require a cocktail of mAbs with broader specificity in order to provide full protection since mAbs are generally specific for single epitopes. Chicken immunoglobulins (IgY) found in egg yolk have been used mainly for treatment of infectious diseases of the gastrointestinal tract. Because the recent epidemic of highly pathogenic avian influenza virus (HPAIV) strain H5N1 has resulted in serious economic losses to the poultry industry, many countries including Vietnam have introduced mass vaccination of poultry with H5N1 virus vaccines. We reasoned that IgY from consumable eggs available in supermarkets in Vietnam could provide protection against infections with HPAIV H5N1. Methods and Findings: We found that H5N1-specific IgY that are prepared from eggs available in supermarkets in Vietnam by a rapid and simple water dilution method cross-protect against infections with HPAIV H5N1 and related H5N2 strains in mice. When administered intranasally before or after lethal infection, the IgY prevent the infection or significantly reduce viral replication resulting in complete recovery from the disease, respectively. We further generated H1N1 virus-specific IgY by immunization of hens with inactivated H1N1 A/PR/8/34 as a model virus for the current pandemic H1N1/09 and found that such H1N1-specific IgY protect mice from lethal influenza virus infection. Conclusions: The findings suggest that readily available H5N1-specific IgY offer an enormous source of valuable biological material to combat a potential H5N1 pandemic. In addition, our study provides a proof-of-concept for the approach using virus-specific IgY as affordable, safe, and effective alternative for the control of influenza outbreaks, including the current H1N1 pandemic.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

主要评分

4.6

评分不足

次要评分

新颖性

重要性

科学严谨性

评价这篇论文

Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses

Tingting Li, Junyu Chen, Qingbing Zheng, Wenhui Xue, Limin Zhang, Rui Rong, Sibo Zhang, Qian Wang, Minqing Hong, Yuyun Zhang, Lingyan Cui, Maozhou He, Zhen Lu, Zhenyong Zhang, Xin Chi, Jinjin Li, Yang Huang, Hong Wang, Jixian Tang, Dong Ying, Lizhi Zhou, Yingbin Wang, Hai Yu, Jun Zhang, Ying Gu, Yixin Chen, Shaowei Li, Ningshao Xia

Summary: Influenza A viruses are a significant global threat, and this study has identified a chimeric monoclonal antibody, C12H5, that offers broad neutralization against H1N1 and H5N1 viruses. The antibody targets a specific epitope on the surface glycoprotein of the virus, leading to control of virus entry and egress. This discovery could have implications for the development of antiviral drugs and broad-protection vaccines against influenza.

NATURE COMMUNICATIONS (2022)